#HEPDART
LightNews LightNews
livermd.bsky.social
@drugbuster21 100% of @HepDART delegates are fully vaccinated. All will be offered daily or at minimum every other day rapid antigen or PCR testing. Hotel staff will also be tested. Can also participate in MEX-DART study
December 3, 2024 at 2:19 AM
livermd.bsky.social
Looking forward to attending #hepdart which starts tomorrow in Kona, HI. Will tweet highlights in the coming week.
December 3, 2024 at 3:03 PM
livermd.bsky.social
William H Prusoff HEP DART lifetime achievement award presented to Dr. Stephen Feinstone #hepdart
December 3, 2024 at 2:58 PM
livermd.bsky.social
Dr. Harvey Alter at podium reciting a poem touting the demise of HCV. Lighter side reflects excitement about future of HCV therapy #hepdart
December 3, 2024 at 2:58 PM
livermd.bsky.social
Dr. Charles Rice (Rockefeller) gives outline of HCV entry. "Role for receptor entry blockers in current landscape controversial" #hepdart
December 3, 2024 at 2:58 PM
livermd.bsky.social
Dr. Paul Pockros gives perspective on lessons from failed HCV clinical trials with cardiotoxicity of BMS-094 as an example. #HCV #hepdart
December 3, 2024 at 2:58 PM
livermd.bsky.social
Dr. Mark Sulkowski gives provocative talk on "forgotten" populations, advocates treatment in many outside baby boomer age #HCV #hepdart
December 3, 2024 at 2:58 PM
livermd.bsky.social
@pgholam: Dr. Adrian DiBisceglie: HBV re-activation and chasm between med/onc and hepatology societies re: screening before chemo #hepdart
December 3, 2024 at 2:58 PM
livermd.bsky.social
Dr. Donald Jensen discusses off-label HCV combos and third party payers. "Anticipate that prior-auth will be a requirement" #HCV #hepdart
December 3, 2024 at 2:58 PM
livermd.bsky.social
Business of antivirals session: off-label combos may be permissible in part due to wording of FDA label for sofosbuvir. #HCV #hepdart
December 3, 2024 at 2:58 PM
livermd.bsky.social
Dr. Ira Jacobson on pts with mild-moderate fibrosis "deferral til IFN-free acceptable and likely a frequent choice" #hepdart #hcv #HepC
December 3, 2024 at 2:58 PM
livermd.bsky.social
Highlight of posters: ribavirin dose reduction does not affect SVR in sofosbuvir trials. RBV weight based dosing best. #hcv #hepdart #HepC
December 3, 2024 at 2:58 PM
livermd.bsky.social
8 weeks of sofosbuvir/ledipasvir+/-RBV= 100% SVR in G1 rx naive non cirrhotics (ph2). ION studies (ph3) will tell more. #hcv #hepdart #HepC
December 3, 2024 at 2:53 PM
livermd.bsky.social
Dr. Thierry Poynard: SVR leads to 1 point decline in METAVIR fibrosis score every 10 years. Curing Fibrosis unmet need. #hepdart #HCV #HepC
December 3, 2024 at 2:53 PM
livermd.bsky.social
Prof. Stephen Locarnini: On origins of HBV. Current HBV may be result of recombinant events in primates and humans #hepdart #HBV #HepB
December 3, 2024 at 2:53 PM
livermd.bsky.social
Dr. Gaston Picchio (Janssen) Q80K decrement in SVR may be partly due to unfavorable characteristics of QUEST-2 subjects #hepdart #HCV #HepC
December 3, 2024 at 2:53 PM
livermd.bsky.social
Dr. Douglas Manion (BMS) daclatasvir is backbone for BMS ph3 trials. Aiming for first all oral approval in G1b (Japan) #hepdart #HepC #HCV
December 3, 2024 at 2:53 PM
livermd.bsky.social
Dr. Daria Hazuda (Merck) MK-5172/MK-8742+/-RBV progressing in ph2 trials. Combo may work without RBV in some eg: G1b #hepdart #HCV #HepC
December 3, 2024 at 2:53 PM
livermd.bsky.social
Dr. Douglas Mayers (Idenix): samatasvir (NS5a) backbone for ph2. Combo simeprevir /NNI TMC647055/r or in-house nucs planned #hepdart #HCV
December 3, 2024 at 2:53 PM
livermd.bsky.social
Dr. Andrea Cox: VIP (vaccine is prevention) trial of novel adenovirus vector prophylactic vaccine. Appears safe so far #hepdart #HepC #HCV
December 3, 2024 at 2:53 PM
livermd.bsky.social
Dr. Houghton: 2nd gen. E1E2 vaccine planned for testing in Canada in next few years. Optimistic based on animal data #hepdart #HCV #HepC
December 3, 2024 at 2:53 PM
livermd.bsky.social
HCV co-discoverer Dr. Michael Houghton: effective vaccine should elicit cellular immune +neutralizing antibody response #hepdart #HepC #HCV
December 3, 2024 at 2:48 PM
livermd.bsky.social
Last day of HepDart 2013. Great location, great weather and high quality meeting...then 15 hour flight back to 10 degree weather #hepdart
December 3, 2024 at 2:48 PM
livermd.bsky.social
In transit to #HEPDART in beautiful Maui where I will be tweeting about all things viral hepatitis and more
December 3, 2024 at 11:34 AM
livermd.bsky.social
Dr. Pockros: estimates 1.8 M treatment naive and 450k experienced #HCV patients of whom 65% are insured out there. #hepdart
December 3, 2024 at 11:34 AM